2 min read.Updated: 16 Sep 2021, 11:26 PM ISTLivemint
Biocon will offer approximately 15% stake to Serum for which it will get committed access to a 100 million doses of vaccines per annum for 15 years
Listen to this article
Biocon Biologics Limited (BBL), a subsidiary of Biocon, on Thursday announced a strategic alliance with Serum Institute Life Sciences (SILS). As per the agreement, BBL will offer approximately 15% stake to SILS for access to a 100 million doses of vaccines per annum for 15 years.
"Under the terms of the agreement, BBL will offer approximately 15% stake to SILS, at a post-money valuation of $4.9 billion, for which it will get committed access to a 100 million doses of vaccines per annum for 15 years, primarily from SILS’s upcoming vaccine facility in Pune with commercialization rights of the SILS vaccine portfolio (including COVID-19 vaccines) for global markets," Biocon said in a statement.
Pursuant to the terms of the agreement, BBL will generate a committed revenue stream and related margins, commencing H2, FY23. Adar Poonawalla will have a Board seat in Biocon Biologics Limited, the company said.
In addition to vaccines, the strategic alliance will also develop antibodies targeting several infectious diseases like Dengue, HIV, etc. The two companies will enter Service Level Agreements (SLAs) for manufacturing and distribution of the vaccines and antibodies.
Vaccines are a complementary business fit to BBL and provides a new dimension to its effort in improving global healthcare. Most recently, Biocon Biologics announced a manufacturing and commercialization partnership in select emerging markets with Boston based Adagio Therapeutics Inc. for ADG20, a novel COVID-19 antibody therapy.
These collaborations support Biocon Biologics’ intent of straddling on both infectious and non-communicable diseases in its quest to impact global health.
On the alliance, Biocon executive chairperson Kiran Mazumdar-Shaw said: “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics. Our shared vision of building large scale businesses having global impact makes it a unique and synergistic value creation opportunity."
Adar Poonawalla, CEO, Serum Institute of India, too commented: “We look forward to complementing each other’s capabilities and capacities in vaccines and biologics, with the objective of addressing inequitable access both in emerging and developed markets for life saving vaccines and biologics."
Biocon Biologics will also establish, at its cost, a vaccine R&D division to support the strategic alliance in developing both vaccines and biologics for communicable diseases.
Additionally, wherever possible, it will make available its cell culture and sterile fill and finish capacities, for vaccine production under the strategic alliance. Both companies believe that this is an alliance that can make significant impact on global healthcare through vaccines and biologics.
Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.
Never miss a story! Stay connected and informed with Mint.
our App Now!!